Efficacy and safety of tadalafil in portopulmonary hypertension

M. Jevnikar (Le Kremlin-Bicêtre, France), N. Ebstein (Le Kremlin-Bicêtre, France), X. Jais (Le Kremlin-Bicêtre, France), A. Boucly (Le Kremlin-Bicêtre, France), D. Montani (Le Kremlin-Bicêtre, France), M. Humbert (Le Kremlin-Bicêtre, France), O. Sitbon (Le Kremlin-Bicêtre, France), L. Savale (Le Kremlin-Bicêtre, France)

Source: International Congress 2018 – Pulmonary hypertension: therapy
Session: Pulmonary hypertension: therapy
Session type: Thematic Poster
Number: 3050
Disease area: Pulmonary vascular diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Jevnikar (Le Kremlin-Bicêtre, France), N. Ebstein (Le Kremlin-Bicêtre, France), X. Jais (Le Kremlin-Bicêtre, France), A. Boucly (Le Kremlin-Bicêtre, France), D. Montani (Le Kremlin-Bicêtre, France), M. Humbert (Le Kremlin-Bicêtre, France), O. Sitbon (Le Kremlin-Bicêtre, France), L. Savale (Le Kremlin-Bicêtre, France). Efficacy and safety of tadalafil in portopulmonary hypertension. 3050

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: